NASDAQ:ARDS Aridis Pharmaceuticals (ARDS) Stock Price, News & Analysis $0.0015 0.00 (0.00%) As of 10/24/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock About Aridis Pharmaceuticals Stock (NASDAQ:ARDS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aridis Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.0015▼$0.001550-Day Range N/A52-Week Range$0.00▼$0.05Volume2 shsAverage Volume23,256 shsMarket Capitalization$77.32 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aridis Pharmaceuticals is a San Diego–based clinical-stage biotechnology company dedicated to developing immunotherapeutic products for the prevention and treatment of life-threatening bacterial and fungal infections. The company’s technology platform leverages monoclonal antibodies and inhaled antifungal formulations to address antibiotic-resistant respiratory pathogens and emerging inhalational threats. Aridis’ research focuses on targeting key virulence factors in organisms such as Pseudomonas aeruginosa and Staphylococcus aureus, with the aim of delivering novel therapeutic approaches for hospital-acquired and ventilator-associated pneumonias, catheter-related bloodstream infections and deep fungal infections of the lung. Among the company’s pipeline candidates, AR-310 is a first-in-class inhaled monoclonal antibody against Pseudomonas aeruginosa, designed for both prophylactic and therapeutic use in patients with cystic fibrosis and those at high risk of ventilator-associated pneumonia. AR-301 is an anti–alpha-toxin antibody targeting Staphylococcus aureus bloodstream infections and antibiotic-resistant strains. AR-501, a human immunoglobulin G designed to neutralize Pseudomonas toxins, is in early-stage development for the prevention of recurrent infections. In parallel, Aridis’ inhaled liposomal amphotericin B formulation advances as a treatment for invasive pulmonary fungal infections, offering targeted delivery with reduced systemic exposure. Aridis collaborates with U.S. government agencies, including the Biomedical Advanced Research and Development Authority (BARDA), and participates in global public–private partnerships to accelerate development of countermeasures against antimicrobial resistance. The company’s clinical trials span multiple geographies across North America and Europe, with regulatory filings planned in key markets. Aridis’ leadership team comprises seasoned biopharmaceutical executives and clinical development experts guiding the company through pivotal studies and toward potential regulatory approvals.AI Generated. May Contain Errors. Read More Aridis Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks2nd Percentile Overall ScoreARDS MarketRank™: Aridis Pharmaceuticals scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Aridis Pharmaceuticals. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Aridis Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aridis Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.05% of the outstanding shares of Aridis Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAridis Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAridis Pharmaceuticals does not currently pay a dividend.Dividend GrowthAridis Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.05% of the outstanding shares of Aridis Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAridis Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for ARDS on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aridis Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.50% of the stock of Aridis Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 9.65% of the stock of Aridis Pharmaceuticals is held by institutions.Read more about Aridis Pharmaceuticals' insider trading history. Receive ARDS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aridis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARDS Stock News HeadlinesAridis Pharmaceuticals, Inc. (ARDS) - Yahoo FinanceJuly 11, 2025 | finance.yahoo.comAridis Provides Corporate UpdateDecember 20, 2024 | globenewswire.comMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff, as the world's biggest car firm prepares to launch a "mind blowing" new product. It has nothing to do with EVs, or self-driving cars. In fact, it's not a car at all... | Altimetry (Ad)Horizon Tech Finance (NASDAQ:HRZN) Stock Quotes, Forecast and News SummaryOctober 11, 2024 | benzinga.comGenor Biopharma Holdings Limited (67N0.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comBreathing easier: Nature-inspired treatments could relieve acute respiratory distressAugust 3, 2024 | msn.comAridis Provides Corporate UpdateJune 24, 2024 | globenewswire.comAridis Pharmaceuticals Inc (ARDS)March 14, 2024 | uk.investing.comSee More Headlines ARDS Stock Analysis - Frequently Asked Questions How have ARDS shares performed this year? Aridis Pharmaceuticals' stock was trading at $0.0001 on January 1st, 2025. Since then, ARDS shares have increased by 1,350.0% and is now trading at $0.0015. How were Aridis Pharmaceuticals' earnings last quarter? Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) announced its earnings results on Wednesday, November, 10th. The company reported ($1.94) earnings per share for the quarter, missing the consensus estimate of ($0.51) by $1.43. The firm earned $0.52 million during the quarter. When did Aridis Pharmaceuticals IPO? Aridis Pharmaceuticals (ARDS) raised $28 million in an initial public offering (IPO) on Tuesday, August 14th 2018. The company issued 2,000,000 shares at $13.00-$15.00 per share. Cantor acted as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers. How do I buy shares of Aridis Pharmaceuticals? Shares of ARDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aridis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aridis Pharmaceuticals investors own include VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Dare Bioscience (DARE), BioCardia (BCDA), Moleculin Biotech (MBRX), SCYNEXIS (SCYX) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings11/10/2021Today10/25/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARDS CIK1614067 Webwww.aridispharma.com Phone(408) 385-1742Fax408-960-3822Employees30Year Founded2003Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares53,321,000Free Float50,388,000Market Cap$77.32 thousand OptionableNot Optionable Beta38.37 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:ARDS) was last updated on 10/26/2025 by MarketBeat.com Staff From Our PartnersU.S. Government Sparking Crypto RallyMissed Bitcoin when it was $100? You’re not alone. Crypto runs in cycles—and the next one is already underw...Crypto 101 Media | SponsoredIt’s Time to Buy “the NVIDIA of Quantum Computing”Yahoo Finance wrote that investing in quantum computing could... "Lead to life-changing returns... and make...Brownstone Research | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuy the dip? Here’s my #1 gold stock“The most obvious opportunity in gold stocks I’ve seen in my career” While everyone is distracted by gold’s...Golden Portfolio | SponsoredThe strategy that wins no matter where the market goesJoel and Adam have built a crypto trading system with a 93% win rate — even through volatile, sideways markets...Crypto Swap Profits | SponsoredTrade this between 9:30 and 10:45 am ESTIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aridis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aridis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.